. Author manuscript; available in PMC: 2010 Sep 1.

Published in final edited form as: Pathol Oncol Res. 2009 Sep;15(3):437–444. doi: 10.1007/s12253-008-9147-4

Table 1.

Immunohistochemical analysis of Hn1 expression in human gliomas

Tissue type		Number of cases	Relative intensity of Hn1 immunoreactivity
Non-neoplastic (negative control)		7	Neurons	2/7 weak
				5/7 absent
			Astrocytes	7/7 absent
			Oligos	7/7 absent
WHO Grade IV Tumor [21]	Glioblastoma Multiforme	11	6 strong
	Glioblastoma Multiforme		2 moderate
			3 weak
WHO Grade III Tumor [21]	Anaplastic Astrocytoma	5	4 strong
	Anaplastic Astrocytoma		1 moderate
	Anaplastic Oligoastrocytoma	1	1 weak
	Anaplastic Oligodendroglioma	11	11 strong
All tumors		28	21 (75%) strong
			3 (11%) moderate
			4 (14%) weak

Criteria: Strong: over 80% of cells have anti-Hn1 immunoreactivity. Moderate: between 21% to 79% of tumor cells have anti-Hn1 immunoreactivity. Weak: less than 20% of cells have anti-Hn1 immunoreactivity.